Shots:

• The companies have signed an 18mos. supply agreement under a 3yrs. master supply and development agreement. Oxford Biomedica to receive $17.95M up front as a capacity reservation fee and expects to receive additional revenue of $41.89M + materials costs for the manufacturing of multiple large-scale batches of AZD1222 until the end of 2021
• Oxford Biomedica will reserve capacity for ~3 manufacturing suites in the Oxbox- for an initial 18mos. period. The new GMP facility is suitable for manufacturing viral vectored vaccines and gene therapy vectors up to 1-000-liter scale.
• The companies may extend the supply period for AZD1222 by a further 18mos. into 2022 and 2023 by mutual agreement. The agreement follows the supply agreement b/w the companies signed on May 28- 2020 for exclusively manufacture AZD1222 at 200L scale and associated process development

­ Ref: Oxford Biomedica | Image: Yahoo Sports